JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

Search

CareDx Inc

Geschlossen

BrancheGesundheitswesen

20.78 -0.38

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

20.23

Max

21.68

Schlüsselkennzahlen

By Trading Economics

Einkommen

-5.8M

-4.1M

Verkäufe

8.3M

108M

KGV

Branchendurchschnitt

14.645

67.147

EPS

0.12

Gewinnspanne

-3.79

Angestellte

761

EBITDA

-5.7M

1.5M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+18.89% upside

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

119M

1.1B

Vorheriger Eröffnungskurs

21.16

Vorheriger Schlusskurs

20.78

Nachrichtenstimmung

By Acuity

65%

35%

314 / 347 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Neutral Evidence

CareDx Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

30. Apr. 2026, 23:08 UTC

Ergebnisse

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30. Apr. 2026, 23:07 UTC

Ergebnisse

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30. Apr. 2026, 22:20 UTC

Ergebnisse

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

30. Apr. 2026, 23:48 UTC

Market Talk

Nikkei May Rise After Gains on Wall Street -- Market Talk

30. Apr. 2026, 23:47 UTC

Market Talk

Global Equities Roundup: Market Talk

30. Apr. 2026, 23:47 UTC

Market Talk

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

30. Apr. 2026, 23:27 UTC

Market Talk

Liontown Lithium Recovery Expected to Improve -- Market Talk

30. Apr. 2026, 23:22 UTC

Ergebnisse

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

30. Apr. 2026, 23:20 UTC

Market Talk

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

30. Apr. 2026, 22:52 UTC

Ergebnisse

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30. Apr. 2026, 22:33 UTC

Ergebnisse

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

30. Apr. 2026, 22:32 UTC

Ergebnisse

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

30. Apr. 2026, 22:32 UTC

Ergebnisse

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

30. Apr. 2026, 22:24 UTC

Akquisitionen, Fusionen, Übernahmen

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

30. Apr. 2026, 22:23 UTC

Akquisitionen, Fusionen, Übernahmen

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

30. Apr. 2026, 22:23 UTC

Akquisitionen, Fusionen, Übernahmen

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

30. Apr. 2026, 22:23 UTC

Akquisitionen, Fusionen, Übernahmen

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

30. Apr. 2026, 22:11 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30. Apr. 2026, 22:11 UTC

Market Talk

Global Equities Roundup: Market Talk

30. Apr. 2026, 22:11 UTC

Market Talk

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

30. Apr. 2026, 22:05 UTC

Ergebnisse

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

30. Apr. 2026, 21:57 UTC

Ergebnisse

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

30. Apr. 2026, 21:56 UTC

Ergebnisse

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

30. Apr. 2026, 21:56 UTC

Ergebnisse

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

30. Apr. 2026, 21:55 UTC

Ergebnisse

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

30. Apr. 2026, 21:54 UTC

Ergebnisse

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

30. Apr. 2026, 21:54 UTC

Ergebnisse

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

30. Apr. 2026, 21:53 UTC

Ergebnisse

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

30. Apr. 2026, 21:49 UTC

Ergebnisse

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

30. Apr. 2026, 21:49 UTC

Ergebnisse

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Peer-Vergleich

Kursveränderung

CareDx Inc Prognose

Kursziel

By TipRanks

18.89% Vorteil

12-Monats-Prognose

Durchschnitt 24.73 USD  18.89%

Hoch 28 USD

Tief 21 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für CareDx Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

6 ratings

2

Buy

4

Halten

0

Sell

Technischer Score

By Trading Central

14.77 / 18.49Unterstützung & Widerstand

Kurzfristig

Neutral Evidence

Mittelfristig

Strong Bearish Evidence

Langfristig

Weak Bearish Evidence

Stimmung

By Acuity

314 / 347 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat